Cost-per-responder analysis of tralokinumab versus dupilumab in patients with moderate-to-severe atopic dermatitis in the US and Canada

被引：0

作者：

Wu, Jashin J. ^{[1
]}

Balu, Sanjeev ^{[2
]}

Larsen, Nikolaj Birk ^{[3
]}

Pulleyblank, Ryan ^{[3
]}

Stromkjaer, Liv ^{[3
]}

Quah, Aron ^{[4
]}

Wiseman, Marni ^{[5
,6
]}

机构：

[1] Univ Miami, Miller Sch Med, Dept Dermatol, Miami, FL USA

[2] LEO Pharma, Madison, NJ USA

[3] NHTA ApS, Copenhagen, Denmark

[4] LEO Pharma, N York, ON, Canada

[5] Univ Manitoba, Dept Med, Sect Dermatol, Winnipeg, MB, Canada

[6] Wiseman Dermatol Res, Winnipeg, MB, Canada

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷

关键词：

matching-adjusted indirect comparison; moderate-to-severe; tralokinumab;

D O I：

10.1093/bjd/ljad498.044

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

544

引用

页码：II42 / II43

页数：2

共 50 条

[21] Dupilumab Treatment Rapidly Improves Itch in Patients With Moderate-to-Severe Atopic Dermatitis
Silverberg, Jonathan I.
Chao, Jingdong
Eckert, Laurent
Chen, Zhen
Ardeleanu, Marius
Shumel, Brad
Plaum, Stefan
Graham, Neil M. H.
Pirozzi, Gianluca
Gadkari, Abhijit
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 29 - 29
[22] Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate-to-severe atopic dermatitis
Staumont-Salle, Delphine
Barbarot, Sebastien
Bouaziz, Jean David
Chan, Chan
Clibborn, Claire
Du-Thanh, Aurelie
Feeney, Claire
Lejeune, Alexandre
Misery, Laurent
Nosbaum, Audrey
Seneschal, Julien
Soria, Angele
Zhang, Fan
JEADV CLINICAL PRACTICE, 2023, 2 (03): : 518 - 530
[23] Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
Hamilton, Jennifer D.
Suarez-Farinas, Mayte
Dhingra, Nikhil
Cardinale, Irma
Li, Xuan
Kostic, Ana
Ming, Jeffrey E.
Radin, Allen R.
Krueger, James G.
Graham, Neil
Yancopoulos, George D.
Pirozzi, Gianluca
Guttman-Yassky, Emma
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (06) : 1293 - 1300
[24] Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Marjolein S. de Bruin-Weller
Esther Serra-Baldrich
Sebastien Barbarot
Susanne Grond
Christopher Schuster
Helmut Petto
Jean-Philippe Capron
Afaf Raibouaa
Thomas Werfel
Dermatology and Therapy, 2022, 12 : 1481 - 1491
[25] Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Ferrucci, Silvia
Casazza, Giovanni
Zussino, Martina
Tavecchio, Simona
Marzano, Angelo V.
Tedeschi, Micol
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)
[26] Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis
Beck, Lisa A.
Muraro, Antonella
Boguniewicz, Mark
Chen, Zhen
Zahn, Joseph
Marco, Ainara Rodriguez
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (01)
[27] Clinically meaningful responses in moderate-to-severe atopic dermatitis patients treated with Dupilumab
de Bruin-Weller, M.
Eckert, L.
Simpson, E. L.
Cork, M. J.
Ardeleanu, M.
Chen, Z.
Shumel, B.
Rossi, A. B.
Graham, N. M. H.
Pirozzi, G.
Gadkari, A.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 116 - 116
[28] Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
de Bruin-Weller, Marjolein S.
Serra-Baldrich, Esther
Barbarot, Sebastien
Grond, Susanne
Schuster, Christopher
Petto, Helmut
Capron, Jean-Philippe
Raibouaa, Afaf
Werfel, Thomas
DERMATOLOGY AND THERAPY, 2022, 12 (06) : 1481 - 1491
[29] COST PER RESPONDER ANALYSIS OF BRODALUMAB COMPARED WITH USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA
Schembri, J.
Barbeau, M.
Gaudet, V
VALUE IN HEALTH, 2018, 21 : S425 - S425
[30] Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis
Nettis, Eustachio
Patella, Vincenzo
Lombardo, Carla
Detoraki, Aikaterini
Macchia, Luigi
Di Leo, Elisabetta
Carbonara, Monica
Canonica, Giorgio W.
Bonzano, Laura
ALLERGY, 2020, 75 (10) : 2653 - 2661

← 1 2 3 4 5 →